ImetelChat

Happy Thanksgiving to all. Well another virtual ASH coming up. So far no indication of KOL formal meeting post ASH and it is likely there will not be one. Nonetheless, it is a premier opportunity for some dramatic PR from Dr. Scarlett and Co and it is likely that strong statements regarding drug suc...

Thanks for posting, I think we have to accept that enrollment is not at the level Geron originally hoped and is due to a combination of factors, the major one probably being COVID but some contribution of the market availability and physician acceptance of Luspatercept is likely playing a role. Give...

CKTC, thanks for your observations and clarifications. It does seem a little peculiar that that Platzbecker presentation abstract has the data cut off we have noted of Feb 2000 without mention of an update. Clearly ASH provides the opportunity to up the TI data to a later data cut off date. Since th...

Recall that Dr. Scarlett said (in what seems like the distant past) that we would be informed when the 50% enrollment goal had been achieved in the MDS study. So far no notification. The shareholders letter addressed the COVID issue which is certainly playing a role but another less discussed reason...

This tender morsel will be irresistible to a large BP that has to see at this point the potential dominance in the area of myeloproliferative disorders. The solid evidence of direct effects on the malignant clone and variable alleles is becoming increasingly apparent. Geron seems to have differentia...

We have an upcoming meeting today. The financial analysts often seem to ask uninformed questions and miss the point and yes I know you read these posts. Often someone else is sitting in because the analyst is busy. So lets get to the positives and negatives. So far with two exceptions (disregarding ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607115/

Check out GRN-163 comments at the conclusion.

HI, thank you for posting this. I have been in medicine a long time. I can tell you that most of the advances I have seen are incremental. A true paradigm shift is a rare event. bp

HI, if Jeremy Smith owns a computer, he knows. He also probably reads this board. bp

HI, yes this apparent intellectual land grab by Dr. T probably caught Geron off guard and was not anticipated. I know you are an expert in IP so wouldn't you find this something unlikely to stand up in court? Was it legal slackness that allowed this to happen? Geron had a reputation for closely guar...

CKTC, thank you for responding. It looks like Imetelstat "knocks back" malignant clones, allowing bone marrow normalcy to recover but that the disease can smolder and later cause clinical recurrence. I was hoping for some discussion from Geron regarding assessment of MRD. Clonal selection is a probl...

Also while we are on the subject of KOL's, Dr. Steensma from the Dana Farber (which also did not contribute patients to either the IMbark or IMerge studies) has taken an interest in Imetelstat. I suspect when we see new sites added to Part II of the MDS trial and perhaps also the IMpactMF we will se...

CKTC, no question the heavyweights are on board. Thank you for emphasizing this. Would you please comment on the following observation? I've been waiting for someone else to confirm this thought but I will present it to you and the board. It was been touched on before but I really think it should be...

Oh I didn't mention that we were being prepared for no KOL meeting this year. I think because there is nothing new to say until there is new data from the PIIIs. Pour a drink, wear a mask and wait. We have had a lot of practice doing just that. bp

First off the abstracts were released a day early. This could give unfair advantage to anyone who expected the abstract release on Nov 5th. I call foul on ASH. Remember when the Mayo abstract info was released inappropriately early? That of course was years ago. So a few curious things about this ye...

Right. A lot. A whole lot. The potential to change the entire natural history of these diseases is apparent. Including impacting the evolution to AML.

Another potential combo? About dasatinib from Wikipedia: “ Dasatinib was developed by collaboration of Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd,[13][14][15] and named for Bristol-Myers Squibb research fellow Jagabandhu Das, whose program leader says that the drug would not have come i...

Every year I ask Dr. Scarlett if there is evidence with the observed disease modification, if some statement can be made regarding the progression of MDS and the transformation to AML can be made. Every year he says there is not enough data. Fair enough. But this year we see an exciting new abstract...